Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
出版年份 2019 全文链接
标题
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
作者
关键词
-
出版物
Thoracic Cancer
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-03-20
DOI
10.1111/1759-7714.13044
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
- (2018) Eric C. Ko et al. CLINICAL CANCER RESEARCH
- Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response
- (2018) Xuanwei Zhang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer
- (2018) Christian Britschgi et al. Radiation Oncology
- Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies
- (2018) Michael Rückert et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Combining immunotherapy and radiotherapy in lung cancer
- (2018) Neeraj Bhalla et al. Journal of Thoracic Disease
- Immune Microenvironment Differences between Squamous and Non-squamous Non-small Cell Lung Cancer and Their Influence on the Prognosis
- (2018) Xiangjiao Meng et al. Clinical Lung Cancer
- Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung
- (2017) Zhigang Yuan et al. Journal of Thoracic Oncology
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
- (2016) Anja Derer et al. Frontiers in Immunology
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started